Open access peer-reviewed Edited Volume

BRCA1 and BRCA2 Mutations - Diagnostic and Therapeutic Implications

Mani T. Valarmathi

Religen Inc. | A Life Science Company, United States of America

Leading cancer and stem cell biologist appointed Director of Research & Development at a life science company in the USA. He was previously an academic at the University of Illinois at Urbana-Champaign, USA. At present, his research is directed toward developing molecular genetic testing for precision and genetic medicine. Member of many prestigious national and international societies, such as the American Association for Cancer Research (AACR) and the International Society for Stem Cell Research (ISSCR).


BRCA Biological Functions BRCA Molecular Profiling BRCA Cancer Susceptibility BRCA Genome Instability BRCA Molecular Genetics BRCA Genetic Testing BRCA Carriers BRCA Counselling BRCA Personalized Medicine BRCA Targeted Pharmacotherapy BRCA Nanomedicine BRCA Cancer Stemness

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Worldwide, breast cancer is the most frequent invasive cancer among women, impacting over two million women each year. It causes the maximum number of cancer-related deaths among women. The incidence of breast cancer varies greatly around the world. Since one woman in eight in the case of the USA or UK is prone to develop breast cancer at some time in her life, it is not surprising that many families have more than one case. Up to 20% of affected women have an affected first-or second-degree relative. Many of these represent chance coincidences, but statistical analysis reveals that in 5 to 10% of women with breast cancer the condition is indeed familial. Initial estimates of risk using a biased set of families for a BRCA1/2 mutation carrier have been variously estimated between 60% and 85%. Researchers and clinicians around the world are working to find better ways to prevent, detect, and treat BRCA-associated hereditary breast and/or ovarian cancer, and to improve the quality of life of patients and survivors. In recent years, there is a substantial amount of development in the area of BRCA-associated hereditary breast and/or ovarian cancer research and its clinical applications, for instance, BRCA cancer biology and genomics; epidemiology and prevention; early detection and screening; as well as diagnosis and treatment. In addition, since the advent of various emerging technologies, such as stem cell technology, genome editing technology, bionanotechnology, as well as personalized medicine, the knowledge gained from such studies not only enhanced our understanding of BRCA-associated cancer but also produced novel insights that could lead to the development and deployment of newer clinical/therapeutic interventions. Therefore, the purpose of this book is to consolidate the recent advances in the area of BRCA-associated cancer biology/therapeutics covering a broad spectrum of interrelated topics and to disseminate that knowledge in a comprehensible way to a great scientific and clinical audience.

Publishing process

Book initiated and editor appointed

Date completed: March 29th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: June 7th 2022

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: August 6th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 25th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 24th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Mani T. Valarmathi

Religen Inc. | A Life Science Company, United States of America

Mani T. Valarmathi is currently Director of Research and Development at Religen Inc., a life science company in Pennsylvania, USA. He began his scientific career as a cancer geneticist but soon became captivated with the emerging and translational fields of stem cell biology, tissue engineering, and regenerative medicine. After obtaining a bachelor’s degree in Chemistry from the University of Madras, Chennai, Tamil Nadu, India, he obtained an MBBS in Medicine and Surgery and an MD in Pathology from the same university. Dr. Valarmathi also holds a Ph.D. in Medical Biotechnology from the All-India Institute of Medical Sciences, New Delhi, India. Over the past two decades, he has had extensive experience in research on various types of stem cells, focused on creating bioengineered human 3D vascularized tissues constructs for implantation purposes. At present, much of his research is directed towards developing innovative molecular genetic testing for precision and genetic medicine. He is a member of many prestigious national and international professional societies and scientific organizations, including the International Society for Stem Cell Research (ISSCR), Tissue Engineering and Regenerative Medicine International Society (TERMIS), American Association for Cancer Research (AACR), American Society for Investigative Pathology (ASIP), American Society for Clinical Pathology (ASCP), American Chemical Society (ACS), European Society of Cardiology (ESC), International Society for Heart Research (ISHR), American Society of Gene & Cell Therapy (ASGCT), and American Heart Association (AHA).

View profile

Book chapters authored 3

Books edited 4

Introducing your Author Service Manager

Ms. Ana Javor

As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors, and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in